GoAI
Get started
Strata Critical Medical, Inc. logo

Strata Critical Medical, Inc.

SRTA

NASDAQHealthcareMedical - Care Facilities

Open in GoAI

Previous close

$6.24

+$0.28 · +4.70%

Aug 21, 4:00 PM ET

SRTA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

32

Expensive

Momentum

44

Neutral

Sentiment

52

Mixed

Risk resilience

41

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of human organs for transplant, utilizing both aerial and ground transportation methods. Founded in 2014, the organization previously operated under the name Blade Air Mobility, Inc. and is set to officially change its name to Strata Critical Medical, Inc. in August of 2025. Its primary corporate office is located in New York, New York.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
US
CEO
Melissa Tomkiel
Listed since
Nov 5, 2019
Employees
327

Market position

Day range

Current $6.24

52-week range

Current $6.24

Open
$6.07
Previous close
$5.96
Volume
1.05M
0.96× average
Average volume
1.09M
Average daily volume
Market cap
539.93M USD
Beta
2.25
Market reference 1
50-day average
$5.4734
+14.01% above average
200-day average
$5.0435
+23.72% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
368.95M USD
P/E (TTM)
12.5×
P/B (TTM)
1.93×
P/S (TTM)
2.11×
EV / EBITDA
-64.63×
Earnings yield
10.43%
Free cash flow yield
-15.11%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
20.56%
Operating margin
-7.97%
Net margin
15.71%
Return on equity
14.82%
Return on assets
12.70%
Return on invested capital
-7.30%

Financial health

Debt / equity
0.02×
Current ratio
6.38×
Altman Z-score
6.21
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends34%-7%-48%-90%Gross margin, FY2021: 20.82%Gross margin, FY2022: 15.24%Gross margin, FY2023: 18.71%Gross margin, FY2024: 23.69%Gross margin, FY2025: 20.86%Operating margin, FY2021: -47.68%Operating margin, FY2022: -36.63%Operating margin, FY2023: -30.25%Operating margin, FY2024: -13.64%Operating margin, FY2025: -11.34%Net margin, FY2021: -79.27%Net margin, FY2022: -18.66%Net margin, FY2023: -24.90%Net margin, FY2024: -10.98%Net margin, FY2025: 20.97%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 20.82%. Gross margin FY2022 15.24%. Gross margin FY2023 18.71%. Gross margin FY2024 23.69%. Gross margin FY2025 20.86%. Operating margin FY2021 -47.68%. Operating margin FY2022 -36.63%. Operating margin FY2023 -30.25%. Operating margin FY2024 -13.64%. Operating margin FY2025 -11.34%. Net margin FY2021 -79.27%. Net margin FY2022 -18.66%. Net margin FY2023 -24.90%. Net margin FY2024 -10.98%. Net margin FY2025 20.97%.

Income trends

Revenue

197.14M USD-20.73%

Operating income

−22.35M USD+34.11%

Net income

41.35M USD+68.65M USD
Income trends across reported periods280.37M USD153.65M USD26.93M USD−99.8M USDRevenue, FY2021: 50.53M USDRevenue, FY2022: 146.12M USDRevenue, FY2023: 225.18M USDRevenue, FY2024: 248.69M USDRevenue, FY2025: 197.14M USDOperating income, FY2021: −24.09M USDOperating income, FY2022: −53.53M USDOperating income, FY2023: −68.12M USDOperating income, FY2024: −33.93M USDOperating income, FY2025: −22.35M USDNet income, FY2021: −40.05M USDNet income, FY2022: −27.26M USDNet income, FY2023: −56.08M USDNet income, FY2024: −27.31M USDNet income, FY2025: 41.35M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 50.53M USD. Revenue FY2022 146.12M USD. Revenue FY2023 225.18M USD. Revenue FY2024 248.69M USD. Revenue FY2025 197.14M USD. Operating income FY2021 −24.09M USD. Operating income FY2022 −53.53M USD. Operating income FY2023 −68.12M USD. Operating income FY2024 −33.93M USD. Operating income FY2025 −22.35M USD. Net income FY2021 −40.05M USD. Net income FY2022 −27.26M USD. Net income FY2023 −56.08M USD. Net income FY2024 −27.31M USD. Net income FY2025 41.35M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue197.14M USD248.69M USD225.18M USD146.12M USD50.53M USD
Cost of goods sold156.02M USD189.77M USD183.06M USD123.85M USD40.01M USD
Gross profit41.13M USD58.92M USD42.12M USD22.28M USD10.52M USD
Research and development3.05M USD3.18M USD4.63M USD5.55M USD1.68M USD
Selling, general, and administrative60.88M USD89.66M USD105.61M USD70.26M USD32.93M USD
Operating expenses63.48M USD92.85M USD110.24M USD75.8M USD34.61M USD
Interest income4.24M USD7.21M USD8.44M USD3.43M USD460K USD
Depreciation and amortization6.9M USD5.96M USD7.11M USD5.73M USD596K USD
Operating income−22.35M USD−33.93M USD−68.12M USD−53.53M USD−24.09M USD
Net income41.35M USD−27.31M USD−56.08M USD−27.26M USD−40.05M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 6 misses, 1 met estimate
Average EPS surprise
-136.37%
11 comparable reports
Latest EPS result
-0.12
Estimate -0.02 · Miss by 500.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.07-0.01-0.08-0.16Q1 '25MetQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual -0.12, estimate -0.12, surprise 0.00%, Met estimate. Q2 2025, reported May 12, 2025: actual -0.04, estimate -0.11, surprise +63.64%, Beat. Q3 2025, reported Aug 5, 2025: actual -0.05, estimate -0.04, surprise -25.00%, Miss. Q4 2025, reported Nov 10, 2025: actual -0.06, estimate -0.02, surprise -200.00%, Miss. Q1 2026, reported Mar 3, 2026: actual -0.062, estimate 0.01, surprise -721.40%, Miss. Q2 2026, reported May 6, 2026: actual 0.03, estimate -0.04, surprise +175.00%, Beat. Q3 2026, reported Aug 4, 2026: actual -0.12, estimate -0.02, surprise -500.00%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate 0.01, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates83.07M70.75M58.42M46.1MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual 54.36M USD, estimate 50.95M USD, surprise +6.68%, Beat. Q2 2025, reported May 12, 2025: actual 54.31M USD, estimate 65.78M USD, surprise -17.45%, Miss. Q3 2025, reported Aug 5, 2025: actual 70.8M USD, estimate 79.87M USD, surprise -11.36%, Miss. Q4 2025, reported Nov 10, 2025: actual 49.3M USD, estimate 60.35M USD, surprise -18.31%, Miss. Q1 2026, reported Mar 3, 2026: actual 66.79M USD, estimate 60.35M USD, surprise +10.67%, Beat. Q2 2026, reported May 6, 2026: actual 67.38M USD, estimate 63.68M USD, surprise +5.82%, Beat. Q3 2026, reported Aug 4, 2026: actual 72.51M USD, estimate 67.61M USD, surprise +7.24%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate 72.67M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

6 ratings
Strong buy00%
Buy6100%
Hold00%
Sell00%
Strong sell00%

SRTA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SRTA

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
10.34M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
10.22M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.97M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
3.79M
Weight
0.03%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.93M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
1.69M
Weight
0.01%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
Dimensional - US Core Equity 2 ETF logoDimensional - US Core Equity 2 ETFDFAC
Market value
1.42M
Weight
0.00%
AUM
49.31B USD
Expense ratio
0.17%
Price / 1D
$45.61+0.46%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
1.4M
Weight
0.09%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research SRTA

research.disclaimer